In Silico藥物發現市場報告：2030 年趨勢、預測與競爭分析

In Silico藥物發現的趨勢和預測

到 2030 年，全球In Silico藥物發現市場預計將達到 55 億美元，2024 年至 2030 年複合年成長率為 10.2%。該市場的主要驅動力是擴大關注減少用藥錯誤、在藥物發現中擴大採用雲端基礎的應用程式以及計算生物學的持續進步。全球In Silico藥物發現市場的未來前景廣闊，委外研發機構、製藥業和學術/研究機構市場都有機會。

• Lucintel 預測，由於在藥物發現過程中擴大採用虛擬篩檢和目標發現，軟體即服務 (SaaS) 將在預測期內實現最高成長。
• 製藥業仍將是該市場的最大部分，因為In Silico藥物發現有助於製藥公司減少開發新藥的時間和成本。
• 由於生物製藥公司研發支出增加、市場參與企業的存在以及大量患有各種慢性病和感染疾病的患者，預計北美在預測期內仍將是最大的地區。

In Silico藥物發現市場的新趨勢

In Silico藥物發現市場出現了一些新興趨勢，標誌著藥物開發和研究的面貌正在改變。

• 人工智慧和機器學習的融合：人工智慧和機器學習擴大融入藥物開發過程中，進一步提高藥物設計的預測準確性和最佳化。這些技術用於分析大型資料集並更準確地預測藥物交互作用的性質。
• 個人化醫療：由於基因組學和生物資訊學的進步，對個人化醫療的興趣與日俱增。In Silico模型可以提高療效，同時最大限度地減少副作用。
• 雲端基礎的平台：雲端基礎的平台由於能夠提供可擴展的In Silico藥物發現解決方案而受到越來越多的關注。此類平台可實現協作、資料共用和計算分析，以進一步簡化藥物發現。
• 高效能運算：高效能運算的應用正在迅速擴展，能夠實現複雜的模擬和大規模資料分析。這些使得In Silico建模更加詳細和準確，從而加速藥物發現和開發。
• 多體學資料的整合：多組體學資料（例如基因組學、蛋白質組學和代謝體學）的整合是In Silico藥物發現中快速發展的部分。這些趨勢使人們能夠更深入地了解生物系統並增強潛在藥物標靶的識別。

這將進一步提高藥物發現過程的技術能力、精確度和效率，並將繼續改變In Silico藥物發現市場的面貌。

In Silico藥物發現市場的最新趨勢

In Silico藥物發現市場的最新趨勢描繪了重大進步和創新的景象。這些因素導致了藥物發現方法的顯著成長。

• 人工智慧演算法的開發：正在開發新的演算法來改進預測建模和虛擬篩檢，例如人工智慧機器學習演算法的開發。這提高了識別候選藥物的速度和準確性，並加速了藥物發現的過程。
• 基因組資料整合：基因組資料整合將為藥物標靶識別和個人化醫療方法帶來更精確的In Silico模型。這一趨勢將有助於開發依賴遺傳資訊的治療方法。
• 基於雲端基礎的解決方案的增加：雲端基礎的解決方案如今非常普遍，為In Silico藥物發現提供了可擴展且靈活的平台。這些解決方案透過資料共用實現研究人員和製藥公司之間的協作。
• 改進的高效能運算：改進的高效能運算技術可以實現複雜的模擬和資料分析，支援詳細的In Silico建模，並加快藥物發現過程。
• 開發多組體學整合工具：整合多體學資料的方法正在迅速發展，提供生物系統的全面視圖。這些進展將提高我們識別藥物標靶和開發有效治療方法的能力。

這些因素透過提高技術能力、增加應用並最終加速藥物發現過程來影響In Silico藥物發現市場。

In Silico藥物發現市場的策略性成長機會

In Silico藥物發現市場列出了主要應用的各種策略成長機會。正確識別和利用機會將促進該市場的進一步擴張和創新。

• 人工智慧主導的藥物發現：人工智慧驅動平台的開發將增加預測建模和虛擬篩檢。這一事實使得藥物發現更加高效並降低了開發成本。
• 個人化醫療解決方案：我們看到個人化醫療In Silico模型的開發不斷成長。透過在個體基因層面上定製藥物發現，公司可以創造出具有更高功效的治療方法。
• 雲端基礎的藥物發現平台：雲端基礎的平台的成長提供了提供可擴展且可存取的藥物發現解決方案的機會。這些平台支援世界各地研究團隊之間的協作和資料共用。
• 高效能運算服務：高效能運算服務可以滿足藥物發現中的複雜模擬和大規模資料分析需求。幫助進行大規模In Silico建模以加速藥物開發。
• 多組體學整合技術：整合多組體學資料和技術的投資創造了為藥物標靶識別和開發過程增加附加價值的機會。這種方法可以更深入地了解生物系統，並顯著改善藥物發現結果。

這些新機會將透過持續的技術開發、擴大的服務範圍和促進藥物發現的創新方法來鞏固In Silico藥物發現市場的成長。

In Silico藥物發現市場推廣因素與挑戰

In Silico藥物發現市場不斷受到技術、經濟和監管方面的影響。此外，我們將說明市場促進因素/挑戰以及如何克服它們。

推動In Silico藥物發現市場的因素包括：

1. 技術進步：技術進步：人工智慧、機器學習和高效能運算的創新是In Silico藥物發現成長的強大驅動力。這些技術提高了預測準確性並簡化了藥物發現過程。

2.研發投入增加：研發投入增加是推動In Silico藥物發現領域成長率的因素之一。這項投資將支持新工具和技術的開發，以提高藥物發現的效率。

3. 對個人化醫療的需求：個人化醫療的概念推動了對In Silico模型的需求，該模型根據個人的基因組成來個性化藥物發現。這可以實現更好的治療，同時減少副作用。

4. 雲端採用：雲端運算的普及為藥物發現提供了可擴展且敏捷的平台。雲端基礎的解決方案促進協作、資料共用和運算分析。

5. 多組體學資料的整合：這種整合使得基於對生物系統的整體理解In Silico藥物發現成為可能。這一趨勢將導致更準確的藥物標靶識別和開發。

In Silico藥物發現市場面臨的挑戰如下。

1.資料隱私和安全：In Silico藥物發現的關鍵挑戰之一是確保所使用的敏感資料的隱私和安全。保護智慧財產權和患者資料對於建立信任和確保合規性至關重要。

2. 整合複雜性：無論如何，整合各種資料來源和技術來建立In Silico模型是一個非常複雜的挑戰。出現了相容性問題，需要持續整合到無縫資料流。

3. 先進技術的高成本：組織經常發現與先進技術和計算資源相關的巨大成本是一個主要障礙。這是In Silico藥物發現的成本和效益之間的平衡。

這些促進因素/挑戰推動了In Silico藥物發現市場，並透過影響成長、創新和整體市場動態的因素來塑造市場。

In Silico藥物發現（按細分市場）

該研究包括按類型、標靶治療領域、工作流程、最終用途和地區對全球In Silico藥物發現的預測。

In Silico藥物發現市場的國家前景

由於人工智慧、機器學習和巨量資料分析的整合，In Silico藥物發現已成為發展最快的領域之一。這些正在改變藥物發現過程，以提高預測準確性並減少時間和成本。主要發展：美國、中國、德國、印度和日本反映了這些國際趨勢，因為他們看到了該領域投資和創新的增加。

• 美國：人工智慧和機器學習在美國正在取得長足進步。其結果是藥物發現領域的預測建模和虛擬篩檢有了顯著改善。先進的演算法、關於困境和生物目標的巨量資料以及其他因素擴大被公司用來更準確、更快速地識別潛在的候選藥物，從而加速藥物開發，成為一種快速且經濟的方法。
• 中國：中國也致力於整合人工智慧和生物資訊學以加速藥物發現。最近的發展推動了預測藥物交互作用和功效的先進計算工具的開發，這是中國實現成為世界製藥創新領導者的夢想的一步。
• 德國：德國在將高效能運算應用於藥物發現過程方面正在取得進展。德國依靠其卓越的研發基礎設施來開發新的In Silico模型，以改善藥物發現目標識別和藥物設計最佳化的過程。
• 印度：建立國家藥物開發和研究能力，重點是使In Silico藥物發現工具的獲取民主化、轉向雲端基礎的平台以及與全球公司的夥伴關係。
• 日本：日本正在透過整合基因組學和人工智慧來加強In Silico藥物發現平台。日本目前的重點是利用此類技術進行精準醫療並加速標靶治療。

常問問題

Q1.市場規模有多大？

答：到 2030 年，全球In Silico藥物發現市場預計將達到 55 億美元。

Q2.市場成長預測如何？

答：2024 年至 2030 年，全球In Silico藥物發現市場預計將以 10.2% 的複合年成長率成長。

Q3.影響市場成長的關鍵促進因素有哪些？

答：這個市場的主要驅動力是人們越來越關注減少用藥錯誤、在藥物發現中擴大採用雲端基礎的應用程式以及計算生物學的持續進步。

Q4.市場的主要細分市場有哪些？

答：In Silico藥物發現市場的未來前景廣闊，為受託研究機構、製藥業和學術/研究機構市場提供了機會。

Q5. 市場上主要企業有哪些？

答：主要的In Silico藥物發現公司有：

• Curia
• Certara
• Charles River Laboratories
• Chemical Computing
• GenScript
• Sygnature Discovery
• Abzena

Q6.未來最大的細分市場是什麼？

答：Lucintel 預測，由於藥物發現過程中擴大採用虛擬篩檢和目標發現，軟體即服務 (SaaS) 將在預測期內實現最高成長。

Q7. 未來五年預計哪個地區的市場最大？

答：由於生物製藥參與企業研發支出增加、市場佔有率強勁以及患有各種慢性和感染疾病的患者人數眾多，北美在預測期內仍然是最大的地區，這種情況很可能會持續下去。

Q8. 可以客製化報告嗎？

答：是的，Lucintel 列出了 10% 的客製化服務，無需額外費用。

目錄

第1章執行摘要

第2章全球In Silico藥物發現市場：市場動態

• 簡介、背景、分類
• 供應鏈
• 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

• 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
• 全球In Silico藥物發現市場趨勢（2018-2023）和預測（2024-2030）
• 按類型分類的全球In Silico藥物發現市場
  • SaaS（Software-as-a-Service）
  • CaaS（Consulting-as-a-Service）
  • 軟體
• 按目標治療領域分類的全球In Silico藥物發現市場
  • 人類免疫力缺乏病毒（HIV）
  • 感染疾病
  • 代謝紊亂
  • 精神障礙
  • 肌肉骨骼疾病
  • 神經系統疾病
  • 腫瘤性疾病
  • 呼吸系統疾病
  • 其他
• 按工作流程分類的全球In Silico藥物發現市場
  • 發現
  • 物體辨識
  • 反向對接
  • 生物資訊學
  • 蛋白質結構預測
  • 目標檢驗
  • 候選人發現
  • 藥效基團
  • 其他
• 按最終用途分類的全球In Silico藥物發現市場
  • 委託研究組織
  • 製藥業
  • 學術研究所
  • 其他

第4章 2018-2030年區域市場趨勢及預測分析

• 按地區分類的全球In Silico發現市場
• 北美In Silico藥物發現市場
• 歐洲In Silico藥物發現市場
• 亞太地區In Silico藥物發現市場
• 其他地區的In Silico藥物發現市場

第5章 競爭分析

• 產品系列分析
• 營運整合
• 波特五力分析

第6章 成長機會與策略分析

• 成長機會分析
  • 全球In Silico藥物發現市場成長機會（按類型）
  • 按目標治療領域分類的全球In Silico藥物發現市場的成長機會
  • 按工作流程分類的全球In Silico藥物發現市場成長機會
  • 全球In Silico藥物發現市場成長機會（按最終用途）
  • 全球In Silico藥物發現市場成長機會（按地區）
• 全球In Silico藥物發現市場的新趨勢
• 戰略分析
  • 新產品開發
  • 擴大全球In Silico藥物發現市場的能力
  • 全球In Silico藥物發現市場的合併、收購和合資企業
  • 認證和許可

第7章主要企業概況

• Curia
• Certara
• Charles River Laboratories
• Chemical Computing
• GenScript
• Sygnature Discovery
• Abzena

In-Silico Drug Discovery Trends and Forecast

The future of the global in-silico drug discovery market looks promising with opportunities in the contract research organizations, pharmaceutical industry, and academic & research institutes markets. The global in-silico drug discovery market is expected to reach an estimated $5.5 billion by 2030 with a CAGR of 10.2% from 2024 to 2030. The major drivers for this market are rising focus towards reduction of medication errors, increasing adoption of cloud-based applications in drug discovery, and on-going advancements in computational biology.

• Lucintel forecasts that software as a service is expected to witness the highest growth over the forecast period due to its increasing adoption for virtual screening and target fising in the drug discovery procedure.
• Within this market, pharmaceutical industry will remain the largest segment due as in-silico drug discovery helps the pharmaceutical companies to reduce the time and cost of developing new drugs.
• North America will remain the largest region over the forecast period due to increasing R&D expenditure by biopharma company, strong presence of market players, and large patient population suffering from various chronic and infectious diseases in the region.

Emerging Trends in the In-Silico Drug Discovery Market

There are several emerging trends in the In-Silico Drug Discovery market, which mark the changing face of the drug development and research landscape.

• AI and Machine Learning Integration: Artificial intelligence and machine learning have started to be integrated more and more into drug development processes, further enhancing predictive accuracy and optimization of drug design. These technologies have been used to analyze large datasets and predict the nature of drug interactions more accurately.
• Personalized Medicine: Interest in personalized medicine is driven by advances in genomics and bioinformatics. In-silico models for tailoring drug discovery and development to individual genetic profiles can enhance efficacy while minimizing adverse effects.
• Cloud-Based Platforms: Cloud-based platforms are of increasing interest due to their scalable delivery of in-silico drug discovery solutions. Such platforms enable collaboration, data sharing, and computational analysis that further streamline drug discovery.
• High-Performance Computing: The application of high-performance computing is growing fast, which allows for complex simulations and large-scale data analysis. These will enable more detailed and correct in-silico modeling, accelerating drug discovery and development.
• Integration of Multi-Omics Data: Integration of multi-omics data, such as genomics, proteomics, and metabolomics, is a rapidly developing area in in-silico drug discovery. These trends allow for a more in-depth understanding of biological systems and enhance the identification of potential drug targets.

This will continue to reshape the face of the In-Silico Drug Discovery market by further developing the technological capabilities, precision, and efficiency of drug discovery processes.

Recent Developments in the In-Silico Drug Discovery Market

Recent developments in the In-Silico Drug Discovery market have painted a picture of great advancement and innovation. These are the factors that contribute to significant growth in methodology for drug discovery.

• AI Algorithm Development: New algorithms, such as developing machine learning algorithms for AI, are being developed to improve predictive modeling and virtual screening. This increases the rate and accuracy of identification of drug candidates and accelerates the processes involved in drug discovery.
• Integration of Genomic Data: The integration of genomic data moves on to more precise in-silico models for identification of drug targets and personalized medicine approaches. This trend contributes to the development of therapies depending on genetic information.
• Increase in Cloud-Based Solutions: Cloud-based solutions are very common today, offering scalable and flexible platforms for in-silico drug discovery. These solutions enable the collaboration of researchers and pharmaceutical companies through data sharing.
• Improvement of high-performance computing: Improvement in high-performance computing technologies can allow complex simulations and data analysis, thus supporting detailed in-silico modeling and speeding up drug development processes.
• Development of Tools for Multi-Omics Integration: Approaches toward integrating multi-omics data are rapidly improving, providing comprehensive views into biological systems. Such development enhances the capability for the identification of drug targets and development of effective therapies.

These factors influence the In-Silico Drug Discovery market by improving technological capabilities, increasing applications, and thus accelerating the process for drug discovery.

Strategic Growth Opportunities for In-Silico Drug Discovery Market

The In-Silico Drug Discovery market presents various strategic growth opportunities from major applications. Proper identification of opportunities and building on them would facilitate further expansion and innovations in this market.

• AI-driven drug discovery: The development of AI-driven platforms will increase predictive modeling and virtual screening. Due to that fact, drug discovery becomes more efficient while development costs decrease.
• Personalized Medicine Solutions: Growth is seen in the development of in-silico models for personalized medicine. Companies can create therapies with much higher effectiveness by tailoring drug discovery at an individual genetic level.
• Cloud-Based Drug Discovery Platforms: The growth of cloud-based platforms presents an opportunity to provide scalable and accessible drug discovery solutions. These platforms support collaboration and data sharing among global research teams.
• High-Performance Computing Services: The requirement for complex simulations and large-scale data analysis in drug discovery can be addressed by leveraging high-performance computing services. It helps perform extensive in-silico modeling and accelerates the development of drugs.
• Multi-omics Integration Technologies: Investments in integrated multi-omics data technologies create opportunities that can bring more value to the process of drug target identification and development. This approach provides a much deeper understanding of biological systems, which will significantly improve the outcomes related to drug discovery.

These emerging opportunities consolidate growth in the In-Silico Drug Discovery market through continued technological development, expanded service offerings, and the furtherance of innovative approaches toward drug development.

In-Silico Drug Discovery Market Driver and Challenges

It is constantly shaped by the facets of technology, economics, and regulation. Further, it describes drivers and challenges associated with the market and how to overcome them.

The factors responsible for driving the in-silico drug discovery market include:

1. Technological advancements: Innovation in AI, machine learning, and high-performance computing-a strong driver of growth in in-silico drug discovery. These technologies enhance predictive accuracy and streamline the process of drug discovery.

2. Increasing R&D Investment: Growing investment in research and development is one of the factors increasing the growth rate in the field of in-silico drug discovery. This investment supports new tool and technology development, hence enhancing efficiency in drug discovery.

3. Demand for Personalized Medicine: The concept of personalized medicine promotes the demand for in-silico models that individualize drug discovery concerning the person's genetic makeup. This offers better treatment with reduced side effects.

4. Cloud Adoption: With widening adoption, cloud computing enables access to scalable and agile platforms for drug discovery. Cloud-based solutions facilitate collaboration, data sharing, and computation analyses.

5. Integration of Multi-omics Data: Such integration thereby allows in-silico drug discovery with a holistic understanding of biological systems. This trend brings better identification and development of drug targets more accurately.

Challenges in the in-silico drug discovery market are:

1. Data Privacy and Security: One of the key challenges with in-silico drug discovery is ensuring privacy and security regarding sensitive data used. The protection of intellectual property and patient data is of utmost importance for building trust and ensuring compliance.

2. Complexity of Integration: In any case, a variety of data sources and technologies being integrated into cohesive in-silico models pose a very complex challenge. Compatibility issues are raised and need to be integrated into a seamless flow of data continuously.

3. High Costs of Advanced Technologies: Organizations often find that huge expenses related to advanced technologies and computational resources are a big obstacle. This balances out with the cost relative to the benefits derived in in-silico drug discovery.

These drivers and challenges are driving the In-Silico Drug Discovery market, shaping it with factors that influence growth, innovation, and overall market dynamics.

List of In-Silico Drug Discovery Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies in-silico drug discovery companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the in-silico drug discovery companies profiled in this report include-

• Curia
• Certara
• Charles River Laboratories
• Chemical Computing
• GenScript
• Sygnature Discovery
• Abzena

In-Silico Drug Discovery by Segment

The study includes a forecast for the global in-silico drug discovery by type, target therapeutic area, workflow, end use, and region.

In-Silico Drug Discovery Market by Type [Analysis by Value from 2018 to 2030]:

• Software as a service
• Consultancy as a service
• Software

In-Silico Drug Discovery Market by Target Therapeutic Area [Analysis by Value from 2018 to 2030]:

• Human Immunodeficiency Virus (HIV)
• Infectious diseases
• Metabolic disorders
• Mental disorders
• Musculoskeletal disorders
• Neurological disorders
• Oncological disorders
• Respiratory disorders
• Others

In-Silico Drug Discovery Market by Workflow [Analysis by Value from 2018 to 2030]:

• Discovery
• Target identification
• Reverse docking
• Bioinformatics
• Protein structure prediction
• Target validation
• Lead discovery
• Pharmacophore
• Others

In-Silico Drug Discovery Market by End Use [Analysis by Value from 2018 to 2030]:

• Contract research organizations
• Pharmaceutical industry
• Academic & research institutes
• Others

In-Silico Drug Discovery Market by Region [Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the In-Silico Drug Discovery Market

In-silico drug discovery has become one of the fast-emerging fields with the integration of AI, machine learning, and big data analytics. These are transforming the processes of drug discovery to increase predictive accuracy and reduce time and cost. Key Developments: United States, China, Germany, India, and Japan reflect these international trends as increased investments and technological innovations have been observed in the area.

• United States: In the US, big strides are being taken in AI and machine learning. Due to that, predictive modeling and virtual screening within the realm of drug search have gotten tremendous improvements. Advanced algorithms, big data on plight and target biology, and other factors have increasingly been employed by firms to identify potential drug candidates more correctly and fast, hence promoting quicker and affordable ways of developing drugs.
• China: China also emphasizes integrating AI with bioinformatics for accelerated drug discovery. Recent years have seen the development of sophisticated computational tools that predict drug interaction and efficacy, a step toward attaining the country's dream of becoming a global leader in pharmaceutical innovation.
• Germany: High-performance computing is increasingly applied to the process of drug discovery in Germany. It bases its hopes on good R&D infrastructure for the development of new in-silico models that help to improve drug target identification and optimization processes in drug design.
• India: India is focused on the democratization of access to in-silico drug discovery tools, a trend towards cloud-based platforms, and partnerships with global firms to build its national capabilities around drug development and research.
• Japan: Japan is enhancing its in-silico drug development platform by incorporating genomics and AI. The immediate focus of the country is to use such technologies for precision medicine and acceleration of targeted therapies.

Features of the Global In-Silico Drug Discovery Market

Market Size Estimates: In-silico drug discovery market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: In-silico drug discovery market size by various segments, such as by type, target therapeutic area, workflow, end use, and region in terms of value ($B).

Regional Analysis: In-silico drug discovery market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, target therapeutic areas, workflow, end uses, and regions for the in-silico drug discovery market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the in-silico drug discovery market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this market or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

FAQ

Q1. What is the in-silico drug discovery market size?

Answer: The global in-silico drug discovery market is expected to reach an estimated $5.5 billion by 2030.

Q2. What is the growth forecast for in-silico drug discovery market?

Answer: The global in-silico drug discovery market is expected to grow with a CAGR of 10.2% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the in-silico drug discovery market?

Answer: The major drivers for this market are rising focus towards reduction of medication errors, increasing adoption of cloud-based applications in drug discovery, and on-going advancements in computational biology.

Q4. What are the major segments for in-silico drug discovery market?

Answer: The future of the in-silico drug discovery market looks promising with opportunities in the contract research organizations, pharmaceutical industry, and academic & research institutes markets.

Q5. Who are the key in-silico drug discovery market companies?

Answer: Some of the key in-silico drug discovery companies are as follows:

• Curia
• Certara
• Charles River Laboratories
• Chemical Computing
• GenScript
• Sygnature Discovery
• Abzena

Q6. Which in-silico drug discovery market segment will be the largest in future?

Answer: Lucintel forecasts that software as a service is expected to witness the highest growth over the forecast period due to its increasing adoption for virtual screening and target fising in the drug discovery procedure.

Q7. In in-silico drug discovery market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to increasing R&D expenditure by biopharma company, strong presence of market players, and large patient population suffering from various chronic and infectious diseases in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the in-silico drug discovery market by type (software as a service, consultancy as a service, and software), target therapeutic area (human immunodeficiency virus (HIV), infectious diseases, metabolic disorders, mental disorders, musculoskeletal disorders, neurological disorders, oncological disorders, respiratory disorders, and others), workflow (discovery, target identification, reverse docking, bioinformatics, protein structure prediction, target validation, lead discovery, pharmacophore, and others), end use (contract research organizations, pharmaceutical industry, academic & research institutes, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
• Market Report

Table of Contents

1. Executive Summary

2. Global In-Silico Drug Discovery Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global In-Silico Drug Discovery Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global In-Silico Drug Discovery Market by Type
  • 3.3.1: Software as a service
  • 3.3.2: Consultancy as a service
  • 3.3.3: Software
• 3.4: Global In-Silico Drug Discovery Market by Target Therapeutic Area
  • 3.4.1: Human Immunodeficiency Virus (HIV)
  • 3.4.2: Infectious diseases
  • 3.4.3: Metabolic disorders
  • 3.4.4: Mental disorders
  • 3.4.5: Musculoskeletal disorders
  • 3.4.6: Neurological disorders
  • 3.4.7: Oncological disorders
  • 3.4.8: Respiratory disorders
  • 3.4.9: Others
• 3.5: Global In-Silico Drug Discovery Market by Workflow
  • 3.5.1: Discovery
  • 3.5.2: Target identification
  • 3.5.3: Reverse docking
  • 3.5.4: Bioinformatics
  • 3.5.5: Protein structure prediction
  • 3.5.6: Target validation
  • 3.5.7: Lead discovery
  • 3.5.8: Pharmacophore
  • 3.5.9: Others
• 3.6: Global In-Silico Drug Discovery Market by End Use
  • 3.6.1: Contract research organizations
  • 3.6.2: Pharmaceutical industry
  • 3.6.3: Academic & research institutes
  • 3.6.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global In-Silico Drug Discovery Market by Region
• 4.2: North American In-Silico Drug Discovery Market
  • 4.2.1: North American In-Silico Drug Discovery Market by Type: Software as a service, Consultancy as a service, and Software
  • 4.2.2: North American In-Silico Drug Discovery Market by End Use: Contract research organizations, Pharmaceutical industry, Academic & research institutes, and Others
• 4.3: European In-Silico Drug Discovery Market
  • 4.3.1: European In-Silico Drug Discovery Market by Type: Software as a service, Consultancy as a service, and Software
  • 4.3.2: European In-Silico Drug Discovery Market by End Use: Contract research organizations, Pharmaceutical industry, Academic & research institutes, and Others
• 4.4: APAC In-Silico Drug Discovery Market
  • 4.4.1: APAC In-Silico Drug Discovery Market by Type: Software as a service, Consultancy as a service, and Software
  • 4.4.2: APAC In-Silico Drug Discovery Market by End Use: Contract research organizations, Pharmaceutical industry, Academic & research institutes, and Others
• 4.5: ROW In-Silico Drug Discovery Market
  • 4.5.1: ROW In-Silico Drug Discovery Market by Type: Software as a service, Consultancy as a service, and Software
  • 4.5.2: ROW In-Silico Drug Discovery Market by End Use: Contract research organizations, Pharmaceutical industry, Academic & research institutes, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global In-Silico Drug Discovery Market by Type
  • 6.1.2: Growth Opportunities for the Global In-Silico Drug Discovery Market by Target Therapeutic Area
  • 6.1.3: Growth Opportunities for the Global In-Silico Drug Discovery Market by Workflow
  • 6.1.4: Growth Opportunities for the Global In-Silico Drug Discovery Market by End Use
  • 6.1.5: Growth Opportunities for the Global In-Silico Drug Discovery Market by Region
• 6.2: Emerging Trends in the Global In-Silico Drug Discovery Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global In-Silico Drug Discovery Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global In-Silico Drug Discovery Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Curia
• 7.2: Certara
• 7.3: Charles River Laboratories
• 7.4: Chemical Computing
• 7.5: GenScript
• 7.6: Sygnature Discovery
• 7.7: Abzena